Table 2.
Relative risk of fracture in postmenopausal women with osteoporosis with zoledronic and versus placebo in HORIZON-PFT1
| Type of fracture |
Number of patients with fractures/total number of patients (%) |
Relative risk or hazard ratio (95% CI) | Pvalue | |
|---|---|---|---|---|
| Placebo | Zoledronic acid | |||
| Morphometric vertebral | 310/2853 (10.9%) | 92/2822 (3.3%) | 0.30 (0.24–038) | <0.001 |
| Hip | 88/3861 (2.5%) | 52/3875 (1.4%) | 0.59 (0.42–0.83) | 0.002 |
| Clinical vertebral | 84/3861 (2.6%) | 19/3875 (0.5%) | 0.23 (0.14–0.37) | <0.001 |
| Nonvertebral | 388/3861 (10.7%) | 292/3875 (8.0%) | 0.75 (0.64–0.87) | <0.001 |
Abbreviation: CI, confidence interval.